Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31331373 | 0.86 | MPL (0.47) | TSHRSMN1; SMN2CYP2D6MPLHIF1A | |
| SCHEMBL2956866 | 0.86 | MPL (0.47) | TSHRSMN1; SMN2CYP2D6MPLHIF1A | |
| SCHEMBL1804448 | 0.84 | TSHR (0.38) | TSHRSMN1; SMN2CYP2D6TTRFABP4 | |
| SCHEMBL11580148 | 0.84 | LMNA (0.39) | TSHRSMN1; SMN2CYP2D6TTRFABP4 | |
| SCHEMBL29674878 | 0.84 | IDO1 (0.47) | TSHRSMN1; SMN2CYP2D6TTRFABP4 | |
| SCHEMBL343463 | 0.84 | IDO1 (0.47) | TSHRSMN1; SMN2CYP2D6TTRFABP4 | |
| Ammonia Solution, Strong SCHEMBL14645369 | 0.84 | MPL (0.46) | CYP2D6MPLHIF1AHSD17B10CTRC | |
| SCHEMBL1804445 | 0.84 | TSHR (0.38) | TSHRSMN1; SMN2CYP2D6TTRFABP4 | |
| SCHEMBL343462 | 0.84 | MYC (0.39) | TSHRSMN1; SMN2CYP2D6TTRFABP4 | |
| SCHEMBL4131552 | 0.84 | TSHR (0.38) | TSHRSMN1; SMN2CYP2D6TTRFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709660-B2 | Polymethine ether compounds | YAMAMOTO CHEMICALS, INC. (JP) | 2010-05-04 | — | — | US | claimed |
| EP-0820284-B1 | BIOLOGICALLY ACTIVE UREIDO DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN SPA (IT) | 2000-02-02 | — | — | EP | claimed |
| CN-108707094-A | A kind of synthesis of 2,6- naphthalenedisulfonic acids and the method for purification | 浙江龙盛化工研究有限公司 | 2018-10-26 | — | — | CN | disclosed |
| US-20170255102-A1 | PATTERN TRIMMING COMPOSITIONS AND METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2017-09-07 | — | — | US | disclosed |
| US-20170255102-A1 | PATTERN TRIMMING COMPOSITIONS AND METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2017-09-07 | — | — | US | disclosed |
| US-20150125985-A1 | ETCHING FLUID AND PRODUCTION METHOD FOR SILICON-BASED SUBSTRATE USING SAME | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2849211-A1 | ETCHING FLUID AND PRODUCTION METHOD FOR SILICON-BASED SUBSTRATE USING SAME | Wako Pure Chemical Industries, Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| CN-104303317-A | Etching solution and method for producing silicon substrate using same | WAKO PURE CHEM IND LTD | 2015-01-21 | — | — | CN | disclosed |
| CN-102417839-A | Fuel antistatic agent and application thereof | OIL RES INST OF THE AIR FORCE PLA | 2012-04-18 | — | — | CN | disclosed |
| EP-2386560-A1 | Crystalline clopidogrel naphthalenesulfonate hydrate, method for preparing same and pharmaceutical composition containing same | Hanmi Holdings Co., Ltd. (KR) | 2011-11-16 | — | — | EP | disclosed |
| CN-1938319-B | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, preparation method thereof, and pharmaceutical composition containing same | HANMI PHARM IND CO LTD | 2010-05-12 | — | — | CN | disclosed |
| US-7446212-B2 | Polymethine ethers | YAMAMOTO CHEMICALS, INC. (JP) | 2008-11-04 | — | — | US | disclosed |
| CN-1938319-A | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, preparation method thereof, and pharmaceutical composition containing same | HANMI PHARM IND CO LTD (KR) | 2007-03-28 | — | — | CN | disclosed |
| EP-1732932-A1 | CRYSTALLINE CLOPIDOGREL NAPHTHALENESULFONATE OR HYDRATE THEREOF, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2006-12-20 | — | — | EP | disclosed |
| US-20060167272-A1 | Intermediates for the production of polymethine compounds containing a desired counter ion with high purity and in high yields; improving the solubility in solvents, the compatibility with resins, the durability and the sensitivity to laser beams | SONY CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1637520-A1 | POLYMETHINE ETHERS | Yamamoto Chemicals, Inc. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005097804-A1 | CRYSTALLINE CLOPIDOGREL NAPHTHALENESULFONATE OR HYDRATE THEREOF, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HANMI PHARM. CO., LTD. (KR) | 2005-10-20 | — | — | WO | disclosed |
| US-20050228012-A1 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same | HANMI PHARM. CO., LTD. | 2005-10-13 | — | — | US | disclosed |
| US-4670600-A | Preparation of substituted amines | SANDOZ PHARM. CORP. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4115058-A | BLEACHES, DETERGENTS | FMC CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228012-A1 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same | P2RY6, NUDT1, AGPS | TSHR 3895/4885SMN1; SMN2 3873/4885CYP2D6 16/4885 |
| US-20060167272-A1 | Intermediates for the production of polymethine compounds containing a desired counter ion with high purity and in high yields; improving the solubility in solvents, the compatibility with resins, the durability and the sensitivity to laser beams | XRCC5, LTB4R2, LTB4R | TSHR 2925/4885SMN1; SMN2 4333/4885CYP2D6 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.